Equities research analysts predict that Cardlytics Inc (NASDAQ:CDLX) will post ($0.15) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Cardlytics’ earnings. The lowest EPS estimate is ($0.24) and the highest is ($0.10). Cardlytics also posted earnings per share of ($0.15) in the same quarter last year. The business is expected to issue its next quarterly earnings report on Tuesday, November 12th.
On average, analysts expect that Cardlytics will report full year earnings of ($0.62) per share for the current fiscal year, with EPS estimates ranging from ($0.80) to ($0.49). For the next financial year, analysts anticipate that the company will report earnings of ($0.14) per share, with EPS estimates ranging from ($0.39) to $0.25. Zacks’ EPS averages are a mean average based on a survey of research analysts that cover Cardlytics.
Cardlytics (NASDAQ:CDLX) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.12) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.35) by $0.23. Cardlytics had a negative net margin of 19.60% and a negative return on equity of 66.01%. The company had revenue of $48.73 million during the quarter, compared to analyst estimates of $43.77 million. During the same quarter last year, the firm posted ($0.21) EPS. The business’s revenue for the quarter was up 37.0% on a year-over-year basis.
Several research analysts have commented on the stock. Raymond James raised their target price on shares of Cardlytics from $24.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. JPMorgan Chase & Co. set a $43.00 target price on shares of Cardlytics and gave the stock a “buy” rating in a report on Friday, August 9th. Bank of America reiterated a “buy” rating and issued a $32.00 target price (up from $22.00) on shares of Cardlytics in a report on Wednesday, July 24th. Zacks Investment Research cut shares of Cardlytics from a “buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Finally, SunTrust Banks raised their target price on shares of Cardlytics from $25.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, August 9th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Cardlytics presently has a consensus rating of “Buy” and a consensus target price of $33.29.
Shares of CDLX traded up $0.72 during midday trading on Monday, hitting $33.98. The stock had a trading volume of 245,100 shares, compared to its average volume of 349,568. Cardlytics has a fifty-two week low of $9.80 and a fifty-two week high of $34.64. The business has a 50-day simple moving average of $29.08 and a two-hundred day simple moving average of $21.33. The firm has a market cap of $765.78 million, a P/E ratio of -15.88 and a beta of 1.76. The company has a current ratio of 2.01, a quick ratio of 2.37 and a debt-to-equity ratio of 0.79.
In other news, CFO David Thomas Evans sold 1,500 shares of the stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $25.18, for a total value of $37,770.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bryce Youngren sold 100,000 shares of the stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $23.04, for a total transaction of $2,304,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 814,894 shares of company stock valued at $23,336,228. Corporate insiders own 21.90% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Gamco Investors INC. ET AL lifted its position in shares of Cardlytics by 2.6% in the second quarter. Gamco Investors INC. ET AL now owns 15,850 shares of the company’s stock worth $412,000 after purchasing an additional 400 shares in the last quarter. Bank of Montreal Can lifted its position in shares of Cardlytics by 16,371.4% in the second quarter. Bank of Montreal Can now owns 1,153 shares of the company’s stock worth $30,000 after purchasing an additional 1,146 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of Cardlytics by 2.3% in the first quarter. SG Americas Securities LLC now owns 61,277 shares of the company’s stock worth $1,014,000 after purchasing an additional 1,402 shares in the last quarter. BlackRock Inc. lifted its position in shares of Cardlytics by 0.4% in the fourth quarter. BlackRock Inc. now owns 422,718 shares of the company’s stock worth $4,578,000 after purchasing an additional 1,610 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. purchased a new stake in shares of Cardlytics in the second quarter worth approximately $60,000. 70.43% of the stock is owned by institutional investors and hedge funds.
Cardlytics Company Profile
Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.
Further Reading: Gross Domestic Product (GDP)
Get a free copy of the Zacks research report on Cardlytics (CDLX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.